|
|
Research progress of Metformin on metabolic markers in newly diagnosed type 2 diabetic patients |
LU Jixuan ZHAN Xiaorong▲ |
Department of Endocrinology, the First Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin 150001, China |
|
|
Abstract Metformin has been used as a hypoglycemic agent for nearly 60 years. A number of Diabetes Research Institute believes that Metformin can be used as first-line drugs in clinical treatment of type 2 diabetes. Therefore, based on the given lifestyle management, Metformin monotherapy is the most preferred regimen in the treatment of newly diagnosed type 2 diabetes patients. In recent years, Metformin has been paid more and more attention in addition to its hypoglycemic effects. Many studies have shown that Metformin also plays a regulatory role in blood pressure, lipids metabolism, body weight and so on. This article reviews the effects of Metformin on related metabolic parameters in patients with newly diagnosed type 2 diabetes mellitus under the influence of standardized lifestyle(diet and exercise).
|
|
|
|
|
[1] Rena G,Hardie DG,Pearson ER. The mechanisms of action of metformin [J]. Diabetologia,2017,60(9):1577-1585.
[2] Wang YW,He SJ,Feng X,et al. Metformin:a review of its potential indications [J]. Drug Des Devel Ther,2017,11:2421-2429.
[3] Singh N,Madhu M,Vanamail P,et al. Efficacy of metformin in improving glycaemic control & perinatal outcome in gestational diabetes mellitus:A non-randomized study [J]. Indian J Med Res,2017,145(5):623-628.
[4] Luizon MR,Eckalbar WL,Wang Y,et al. Genomic Characterization of Metformin Hepatic Response [J]. PLoS Genet,2016,12(11):e1006449.
[5] An H,He L. Current understanding of metformin effect on the control of hyperglycemia in diabetes [J]. J Endocrinol,2016,228(3):R97.
[6] Zheng J,Woo S L,Hu X,et al. Metformin and metabolic diseases:a focus on hepatic aspects [J]. Front Med,2015, 9(2):173-186.
[7] Hannah R. Bridges,Andrew J.Y. Jones,Michael N. Pollak,et al. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria [J]. Biochem J,2014, 462(Pt 3):475-487.
[8] Kinaan M,Ding H,Triggle CR. Metformin:An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium [J]. Med Princ Pract,2015,24(5):401-415.
[9] Madiraju AK,Erion DM,Rahimi Y,et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase [J]. Nature,2014,510(7506):542-546.
[10] Ross FA,Mackintosh C,Hardie DG. AMP-activated protein kinase:a cellular energy sensor that comes in twelve flavours [J]. FEBS J,2016,283(16):2987-3001.
[11] Zhang CS,Li M,Ma T,et al. Metformin Activates AMPK through the Lysosomal Pathway [J]. Cell Metab,2016,24(4):521-522.
[12] Pavlidou T,Rosina M,Fuoco C,et al. Regulation of myoblast differentiation by metabolic perturbations induced by metformin [J]. PLoS One,2017,12(8):e0182475.
[13] Nostell KEA,Lindåse SS,Bröjer JT. Blood pressure in Warmblood horses before and during a euglycemic-hyperinsulinemic clamp [J]. Acta Vet Scand,2016,58(1):65.
[14] Patel JP,Lee EH,Mena CI,et al. Effects of metformin on endothelial health and erectile dysfunction [J]. Transl Androl Urol,2017,6(3):556-565.
[15] Majithiya JB,Balaraman R. Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats [J]. Life Sci,2006,78(22):2615-2624.
[16] Petersen JS,Andersen D,Muntzel MS,et al. Intracerebr-oventricular metformin attenuates salt-induced hypertension in spontaneously hypertensive rats [J]. Am J Hypertens,2001,14(11 Pt 1):1116-1122.
[17] Lee JM,Peuler JD. A possible indirect sympathomimetic action of metformin in the arterial vessel wall of spontanously hypertensive rats [J]. Life Sci,2001,69(9):1085-1092.
[18] Thomopoulos C,Katsimagklis G,Makris T. Metformin and blood pressure lowering:a questioned association [J]. J Hypertens. 2017,35(1):27-28.
[19] Valencia WM,Palacio A,Tamariz L,et al. Metformin and ageing:improving ageing outcomes beyond glycaemic control [J]. Diabetologia,2017,60(9):1630-1638.
[20] Zahra K,Abdolkarim M,Anvarsadat K,et al. The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes:HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin [J]. PloS One,2016,11(3):e0151543.
[21] Patel VI,Patel KP,Makadia MG,et al. Levels of Apolipoprotein A1,B100 and Lipoprotein (a)in Controlled and Uncontrolled Diabetic Patients and in Non-Diabetic Healthy People [J]. J Clin Diagn Res,2017,11(2):BC01-BC05.
[22] Tani S,Yagi T,Atsumi W,et al. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus:a cross-sectional study [J]. Cardiovasc Diabetol,2017,16(1):123.
[23] Zheng S,Zhou H,Han T,et al. Clinical characteristics and beta cell function in Chinese patients with newly diagnosed type 2 diabetes mellitus with different levels of serum triglyceride [J]. BMC Endocr Disord,2015,15(1):21.
[24] Tomkin GH,Owens D. Diabetes and dyslipidemia:characterizing lipoprotein metabolism [J]. Diabetes Metab Syndr Obes,2017,10:333-343.
[25] Ye W,Ramos E H,Wong B C,et al. Beneficial Effects of Metformin and/or Salicylate on Palmitate- or TNF-αInduced Neuroinflammatory Marker and Neuropeptide Gene Regulation in Immortalized NPY/AgRP Neurons [J]. PloS One,2016,11(11):e0166973.
[26] Li W,Yang X,Tao Z,et al. TNF stimulates endothelial palmitic acid transcytosis and promotes insulin resistance [J]. Scientific Rep,2017,7:44659.
[27] Seifarth C,Schehler B,Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity [J]. Exp Clin Endocrinol Diabetes,2013,121(1):27-31.
[28] Malin SK,Nightingale J,Choi SE,et al. Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults [J]. Obesity,2013,21(1):93-100.
[29] Hundal RS,Inzucchi SE. Metformin:new understandings,new uses [J]. Drugs,2003,63(18):1879-1894.
[30] Troncone M,Cargnelli SM,Villani LA,et al. Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer(NSCLC)to cytotoxic therapy:translational biology and rationale for current clinical trials [J]. Oncotarget,2017,8(34):57733-57754.
[31] Elarabey AA. New insight for metformin against bladder cancer [J].Genes Environ,2017,39(1):13.
[32] Esmaeilzadeh S,Gholinezhadchari M,Ghadimi R. The Effect of Metformin Treatment on the Serum Levels of Homocysteine,Folic Acid,and Vitamin B12 in Patients with Polycystic Ovary Syndrome [J]. J Hum Reprod Sci,2017, 10(2):95-101. |
|
|
|